###begin article-title 0
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK2</italic>
Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy
###end article-title 0
###begin p 1
Conceived and designed the experiments: FM KR CP. Performed the experiments: AE KR. Analyzed the data: AE KR. Contributed reagents/materials/analysis tools: FM KR CP. Wrote the paper: AE KR.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 357 365 <span type="species:ncbi:9606">patients</span>
Among gynecologic cancers, ovarian cancer is the second most common and has the highest death rate. Cancer is a genetic disorder and arises due to the accumulation of somatic mutations in critical genes. An understanding of the genetic basis of ovarian cancer has implications both for early detection and for therapeutic intervention in this population of patients.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 181 185 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK2</italic>
###xml 187 191 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 333 337 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 878 882 876 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK2</italic>
Fifteen ovarian cancer cell lines, commonly used for in vitro experiments, were screened for mutations using bidirectional direct sequencing in all coding regions of BRAF, MEK1 and MEK2. BRAF mutations were identified in four of the fifteen ovarian cancer cell lines studied. Together, these four cell lines contained four different BRAF mutations, two of which were novel. ES-2 had the common B-Raf p.V600E mutation in exon 15 and Hey contained an exon 11 missense mutation, p.G464E. The two novel B-Raf mutants identified were a 5 amino acid heterozygous deletion p.N486-P490del in OV90, and an exon 4 missense substitution p.Q201H in OVCAR 10. One of the cell lines, ES-2, contained a mutation in MEK1, specifically, a novel heterozygous missense substitution, p.D67N which resulted from a nt 199 G-->A transition. None of the cell lines contained coding region mutations in MEK2. Functional characterization of the MEK1 mutant p.D67N by transient transfection with subsequent Western blot analysis demonstrated increased ERK phosphorylation as compared to controls.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 170 174 170 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 289 293 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 298 304 298 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1/2</italic>
###xml 127 132 <span type="species:ncbi:9606">human</span>
###xml 426 434 <span type="species:ncbi:9606">patients</span>
In this study, we report novel BRAF mutations in exon 4 and exon 12 and also report the first mutation in MEK1 associated with human cancer. Functional data indicate the MEK1 mutation may confer alteration of activation through the MAPK pathway. The significance of these findings is that BRAF and MEK1/2 mutations may be more common than anticipated in ovarian cancer which could have important implications for treatment of patients with this disease and suggests potential new therapeutic avenues.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 163 166 163 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Jemal1">[1]</xref>
###xml 112 117 <span type="species:ncbi:9606">women</span>
Ovarian cancer is the second most common gynecologic cancer in the United States affecting approximately 22,000 women each year causing an estimated 15,200 deaths [1]. Cancer is a genetic disorder arising from the accumulation of somatic mutations in genes involved in critical cellular pathways. These mutations typically result in proteins which exhibit their oncogenic effect by altering signaling through vital transduction networks, or in haploinsufficiency of critical tumor suppressor proteins.
###end p 9
###begin p 10
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 243 246 243 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Davies1">[2]</xref>
###xml 247 250 247 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Ikediobi1">[5]</xref>
###xml 252 256 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 256 259 256 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Davies1">[2]</xref>
###xml 261 267 261 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 267 270 267 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Ikediobi1">[5]</xref>
###xml 271 274 271 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Nakayama1">[9]</xref>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 280 283 280 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Ikediobi1">[5]</xref>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Saito1">[10]</xref>
###xml 291 295 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Schondorf1">[11]</xref>
###xml 297 301 297 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 301 304 301 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Ikediobi1">[5]</xref>
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Tworek1">[12]</xref>
###xml 312 316 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Singer2">[13]</xref>
###xml 321 325 321 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 325 328 325 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Davies1">[2]</xref>
###xml 329 332 329 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Sieben1">[4]</xref>
###xml 364 368 364 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 931 935 931 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Yoon1">[14]</xref>
###xml 1114 1118 1114 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Hoshino1">[15]</xref>
###xml 1253 1257 1253 1257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-SeboltLeopold1">[16]</xref>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 1074 1079 <span type="species:ncbi:9606">human</span>
Understanding the genetic basis of ovarian cancer has implications both for early detection, as well as for therapeutic intervention in this population of patients. Genes which have been found somatically mutated in ovarian cancer include KRAS[2]-[5], NRAS[2], PIK3CA[5]-[9], PTEN[5], [10], [11], TP53[5], [12], [13] and BRAF[2]-[4]. B-Raf, the protein product of BRAF, is a serine/threonine protein kinase and the first in the mitogen-activated protein kinase (MAPK) cascade which is one of the many downstream effector pathways of Ras. Extracellular stimuli leads to the activation of Ras, which in turn activates Raf (A-Raf, B-Raf, and/or C-Raf-1). Raf then phosphorylates and activates MEK1 and/or MEK2 (MAPK kinase). MEK1 and MEK2 are threonine/tyrosine kinases with both isoforms having the ability to phosphorylate and activate ERK1 and ERK2 (MAPK). ERK, once activated by MEK, has numerous cytosolic and nuclear substrates [14]. Aberrant upstream signaling resulting in hyperactivated ERK plays a key role in the pathogenesis and progression of approximately 30% of human cancers, including ovarian cancer [15]. As a result, this pathway has been an attractive target for the development of small molecule inhibitors for the treatment of cancer [16].
###end p 10
###begin p 11
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK2</italic>
###xml 294 297 294 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Singer1">[3]</xref>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Ho1">[17]</xref>
###xml 363 367 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 372 376 372 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK2</italic>
###xml 399 403 399 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 651 655 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-RodriguezViciana1">[18]</xref>
###xml 776 782 776 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1/2</italic>
###xml 826 830 826 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 963 967 963 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 1041 1045 1041 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1050 1056 1050 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1/2</italic>
###xml 984 989 <span type="species:ncbi:9606">human</span>
###xml 1193 1201 <span type="species:ncbi:9606">patients</span>
Genes comprising the MAPK pathway, BRAF, MEK1 and MEK2, were systematically scanned for mutations in 15 ovarian cancer cell lines using bidirectional direct sequencing of all exons. Previous reports have demonstrated that B-Raf is mutated in approximately 28-37% of low grade serous carcinomas [3], [17]. With this information, our search was expanded to include MEK1 and MEK2, two genes along with BRAF, which we have recently determined to be causal for cardio-facio-cutaneous (CFC) syndrome (MIM 115150), a multiple congenital anomaly syndrome whereby individuals have characteristic craniofacial dysmorphia, heart defects and ectodermal anomalies [18]. Interestingly, unlike germline mutations identified in CFC syndrome, no somatic mutations have ever been identified in MEK1/2 in any cancer type. In our analysis, novel BRAF mutations were identified in exon 4 and exon 12 of two separate cell lines. In addition, we report the first functional mutation in MEK1 associated with human cancer. The significance of these findings is that BRAF and MEK1/2 mutations may be more common than previously recognized in ovarian cancer, which could have important implications for the treatment of patients with ovarian cancer.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
BRAF and MEK1 Mutations
###end title 13
###begin p 14
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 192 200 192 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001279-g001">Figure 1</xref>
###xml 236 240 236 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 268 272 268 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 417 426 415 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001279-g001">Figure 1A</xref>
###xml 516 525 514 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001279-g001">Figure 1B</xref>
###xml 557 561 555 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 765 774 761 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001279-g001">Figure 1C</xref>
###xml 972 981 966 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001279-g001">Figure 1D</xref>
Genomic DNA from 15 ovarian cancer cell lines was screened for BRAF mutations in coding exons 1-18. Four mutations were identified in four individual cell lines: OVCAR 10, OV90, Hey and ES-2 (Figure 1). None of the other cell lines had BRAF mutations. Two of the four BRAF mutations identified were novel. OVCAR 10 contained a nt 603 G-->T transversion causing a heterozygous missense substitution p.Q201H in exon 4 (Figure 1A). OV90 contained a novel heterozygous 5 amino acid deletion, p.N486-P490del, in exon 12 (Figure 1B). In addition to the two novel BRAF mutations identified, two additional mutations which have been previously reported in cancer were identified. Hey contained a nt 1391 G-->A transition resulting in an exon 11 missense mutation, p.G464E (Figure 1C). The electropherogram demonstrated loss of heterozygosity at this locus. ES-2 contained an exon 15, T-->A transversion at nt 1799, substituting glutamic acid for valine at position 600 (p.V600E) (Figure 1D). None of these mutations were identified in the controls.
###end p 14
###begin title 15
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
Electropherograms of BRAF and MEK1 mutations compared to normal controls.
###end title 15
###begin p 16
###xml 5 9 5 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 562 567 554 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1,</italic>
Four BRAF mutations were identified in four individual cell lines. A) OVCAR 10 contained a nt 603 G-->T transversion causing a heterozygous missense substitution p.Q201H in exon 4. B) OV90 contained a novel heterozygous deletion starting at nt 1457 (arrow) resulting in a 5 amino acid deletion, p.N486-P490del, in exon 12. C) Hey contained a nt 1391 G-->A transition resulting in loss of heterozygosity. D) ES-2 contained an exon 15, T-->A transversion at nt 1799, substituting glutamic acid for valine at position 600 (p.V600E). E) A nt 199 G-->A transition in MEK1, exon 2 resulted in a heterozygous missense substitution, p.D67N.
###end p 16
###begin p 17
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK2</italic>
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 255 264 253 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001279-g001">Figure 1E</xref>
###xml 356 360 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK2</italic>
All eleven coding exons of MEK1 and MEK2 were also sequenced in the same cell lines and controls. One mutation in MEK1 was identified in ES-2 consisting of a novel heterozygous missense substitution, p.D67N, which resulted from a nt 199 G-->A transition (Figure 1E). No other nonsynonymous substitutions in MEK1 were identified. All eleven coding exons of MEK2 were sequenced and no nonsynonymous substitutions were identified.
###end p 17
###begin title 18
Nucleotide Variation
###end title 18
###begin p 19
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 133 140 133 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001279-t001">Table 1</xref>
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 149 156 149 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001279-t002">Table 2</xref>
###xml 163 167 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK2</italic>
###xml 169 176 169 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001279-t003">Table 3</xref>
###xml 711 718 709 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001279-t002">Table 2</xref>
In addition to these mutations, a total of four different synonymous single nucleotide polymorphisms (SNPs) were identified in BRAF (Table 1), MEK1 (Table 2), and MEK2 (Table 3). Three of these four SNPs were found in five or more of the fifteen cell lines and have been previously reported (). In order of frequency, the three synonymous database SNPs include: i) MEK2 p.I220I (rs10250) present in 11 of the 15 cell lines (73%), ii) BRAF p.G634G (rs9648696) found in six of the 15 cell lines (40%) and, iii) MEK2 p.D151D (rs17851657) identified in five of the 15 cell lines (33%). There was one uniquely identified MEK1 SNP in OVCAR 10 resulting from a nt 348 heterozygous G-->A transition in exon 3, p.Q113Q (Table 2). All synonymous SNPs were characterized by SIFT (Sorting Intolerant From Tolerant) and determined to be tolerated.
###end p 19
###begin title 20
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
BRAF sequence variations identified in ovarian cancer cell lines.
###end title 20
###begin p 21

###end p 21
###begin p 22
blocks.fhcrc.org/sift/SIFT.html
###end p 22
###begin title 23
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
MEK1 sequence variations identified in ovarian cancer cell lines.
###end title 23
###begin p 24

###end p 24
###begin p 25
blocks.fhcrc.org/sift/SIFT.html
###end p 25
###begin title 26
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK2</italic>
MEK2 synonymous SNPs identified in ovarian cancer cell lines.
###end title 26
###begin p 27

###end p 27
###begin p 28
blocks.fhcrc.org/sift/SIFT.html
###end p 28
###begin title 29
Functional Characterization of Mutants
###end title 29
###begin p 30
SIFT was utilized to characterize the functional significance of the nonsynonymous amino acid substitutions identified in B-Raf and MEK1. B-Raf p.G464E, p.N486-P490del, p.V600E and MEK1 p.D67N were predicted to be deleterious substitutions causing an alteration of protein function, whereas B-Raf p.Q201H was predicted to be tolerated.
###end p 30
###begin p 31
###xml 247 255 247 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001279-g002">Figure 2</xref>
To corroborate the functional alteration of the novel MEK1 p.D67N mutant identified in ES-2, transient transfection of HEK 293T cells with subsequent Western blot analysis demonstrated increased kinase activity as measured by ERK phosphorylation (Figure 2). The MEK1 p.D67N mutant had increased ERK phosphorylation compared to wildtype MEK1. The level of ERK phosphorylation was lower than the CFC MEK1 p.Y130C mutant which is known to have a high level of activity (positive control).
###end p 31
###begin title 32
Functional characterization of the MEK1 p.D67N mutant identified in ES-2.
###end title 32
###begin p 33
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-RodriguezViciana1">[18]</xref>
###xml 586 590 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-RodriguezViciana1">[18]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human embryonic kidney 293T cells were transiently transfected with empty vector, wild-type MEK1, MEK1 p.Y130C (positive control mutant which has known high activity level[18]) and the MEK1 p.D67N mutant. ERK (p44 ERK1 and p42 ERK2) phosphorylation was assayed by Western blotting using phospho-specific antibodies. The p.D67N MEK1 mutant had increased ERK phosphorylation compared to the level induced by empty vector and wildtype MEK1. The level of ERK phosphorylation induced by p.D67N MEK1 is slightly less than the CFC MEK1 p.Y130C mutant which is known to have increased activity [18]. Myc-tagged MEK1 is shown for transfection efficiency and total ERK is shown as a loading control.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Hoshino1">[15]</xref>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 308 312 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 389 392 389 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Davies1">[2]</xref>
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Russell1">[19]</xref>
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Thomas1">[23]</xref>
Altered signaling through the MAPK pathway in cancer often results from mutations in upstream components of ERK, including K-Ras, N-Ras, H-Ras, C-Raf-1 and B-Raf [15]. Molecular studies of ovarian cancer cell lines and tumor specimens have identified genetic mutations in some of these genes, KRAS, NRAS and BRAF , which result in the alteration of signaling through this critical pathway [2], [19]-[23].
###end p 35
###begin p 36
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 252 256 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 428 432 428 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Wellbrock1">[24]</xref>
###xml 545 549 545 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 891 895 891 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Wan1">[25]</xref>
###xml 574 579 <span type="species:ncbi:9606">human</span>
Somatic mutations in BRAF have been reported at a high frequency in numerous cancers including melanoma, thyroid, colorectal and ovarian. Approximately 70 missense mutations affecting 34 codons have been reported (). In cancer, the majority of somatic BRAF mutations result in missense substitutions found in, but not limited to, exon 11 (the glycine-rich loop) and exon 15 (the activation segment) in the protein kinase domain [24]. One missense mutation in exon 15 resulting in a missense substitution, B-Raf p.V600E, accounts for over 90% of BRAF mutations identified in human cancer. The crystal structure of B-Raf shows that the activation segment is held in an inactive conformation by association with the G-loop. Mutations in these two regions, the glycine-rich loop and the activation segment, are believed to disrupt this interaction, converting B-Raf into its active conformation [25].
###end p 36
###begin p 37
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 284 288 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-RodriguezViciana1">[18]</xref>
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Niihori1">[26]</xref>
###xml 528 532 528 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 694 698 694 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-RodriguezViciana1">[18]</xref>
###xml 700 704 700 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Niihori1">[26]</xref>
###xml 744 748 744 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
In addition to somatic mutations, germline mutations in BRAF have recently been identified as causing CFC syndrome, a multiple congenital anomaly disorder whereby individuals have characteristic craniofacial dysmorphisms, cardiac defects, ectodermal anomalies and developmental delay [18], [26]. Most of the mutations in CFC syndrome fall outside the exon 11 and exon 15 protein kinase domain. The most common causative CFC mutation, p.Q257R, resides in exon 6 of the cysteine-rich domain. Like most cancer-causing mutations in BRAF, biochemical studies have determined that most novel CFC B-Raf mutant proteins have increased kinase activity relative to the kinase activity of wild-type B-Raf [18], [26]. These studies punctuate the fact that BRAF mutations occur not only somatically but also in the germline, and that mutations that confer increased kinase activity are not restricted to those typically associated with cancer.
###end p 37
###begin p 38
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 218 222 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 289 293 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Lau1">[27]</xref>
###xml 560 563 560 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Singer1">[3]</xref>
###xml 565 569 565 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Ho1">[17]</xref>
###xml 732 736 732 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 795 799 795 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Buick1">[28]</xref>
###xml 960 964 960 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Nava1">[29]</xref>
###xml 1043 1047 1043 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Provencher1">[30]</xref>
###xml 1261 1265 1261 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Cruz1">[31]</xref>
###xml 1267 1271 1267 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Trovisco1">[32]</xref>
###xml 1431 1436 <span type="species:ncbi:9606">human</span>
Bidirectional sequencing of all the coding exons of BRAF in 15 well-characterized and highly utilized ovarian cancer cell lines identified four cell lines with BRAF mutations. Only one cell line had the common exon 15 BRAF mutation. ES-2 which is derived from ovarian clear cell carcinoma [27] had the common heterozygous p.V600E missense mutation. Previous reports have demonstrated that B-Raf is mutated most commonly in low grade ovarian serous carcinomas with a frequency of approximately 28-37% and that all mutations are the common B-Raf p.V600E variant [3], [17]. Interestingly, the two serous-derived cell lines examined in this study (Hey and OV90) did not have the common B-Raf p.V600E mutation; however, both did contain BRAF mutations. Hey, derived from a papillary serous carcinoma [28], contained an exon 11 missense mutation, p.G464E. This missense mutation has been described previously () and is also a codon which is mutated in CFC syndrome ([29]; Rauen, unpublished data). OV90 which is derived from a serous adenocarcinoma [30] contained a novel mutation in exon 12 resulting in a heterozygous five amino acid deletion, p.N486-P490del. Although extremely rare, somatic exon 15 B-Raf in-frame deletion-insertions have been reported in cancer [31], [32]. In addition, we identified two CFC individuals with small in-frame deletions in exon 11 (Rauen, unpublished data). Finally, OVCAR 10, which is derived from a human ovarian epithelial cancer, had a unique heterozygous missense substitution p.Q201H in exon 4. This nonsynonymous SNP has not been identified in cancer or CFC syndrome and was determined to be tolerated by SIFT, so perhaps B-Raf p.Q210H represents a rare polymorphism.
###end p 38
###begin p 39
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 297 301 297 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
Only two of the ovarian cancer cell lines had mutations in the typically affected exon 11/15 regions in the B-Raf protein kinase domain. This finding raises the possibility that cancer-associated BRAF mutations outside of exon 11/15 may be more common than anticipated. Since the vast majority of BRAF mutation survey studies published are restricted to exons 11 and 15, other possible mutations outside these regions may be overlooked.
###end p 39
###begin p 40
###xml 249 253 249 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Ng1">[33]</xref>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Ng2">[34]</xref>
###xml 265 269 265 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 390 394 390 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 756 760 756 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-RodriguezViciana1">[18]</xref>
###xml 762 766 762 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Niihori1">[26]</xref>
To explore the functional significance of these novel B-Raf mutants, all those identified in this study were analyzed by SIFT (), an online mutation analysis program that predicts the functional consequence of nonsynonymous amino acid substitutions [33], [34]. All BRAF mutations identified were predicted to have altered protein function except for p.Q201H. The functional significance of BRAF coding mutations in exons other than 11 and 15 is supported by biochemical studies of novel germline mutations identified in CFC. Like somatic mutations, most CFC germline mutations confer an increased kinase activity, while some are kinase impaired. However, all CFC mutations which have been biochemically characterized alter protein function to some extent ([18], [26]; Rauen, unpublished data).
###end p 40
###begin p 41
###xml 170 176 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1/2</italic>
###xml 566 570 564 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-RodriguezViciana1">[18]</xref>
###xml 777 781 775 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Nava1">[29]</xref>
###xml 800 804 798 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 1169 1173 1167 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Bignell1">[35]</xref>
###xml 1174 1178 1172 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Stephens1">[38]</xref>
###xml 1352 1356 1350 1354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-RodriguezViciana1">[18]</xref>
###xml 1358 1362 1356 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Nava1">[29]</xref>
###xml 1364 1368 1362 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Narumi1">[39]</xref>
###xml 1479 1487 1477 1485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1645 1649 1643 1647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-RodriguezViciana1">[18]</xref>
###xml 1860 1864 1858 1862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Delaney1">[40]</xref>
###xml 1865 1869 1863 1867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Mansour1">[42]</xref>
B-Raf has only two known downstream effectors, MEK1 and MEK2. In an effort to characterize the mutation spectrum of the MAPK pathway in ovarian cancer, we also sequenced MEK1/2 and identified a novel MEK1 heterozygous missense substitution, p.D67N, in ES-2 which resulted from a nt 199 G-->A transition. This is the first identified functional MEK mutation associated with cancer and does not represent a rare polymorphism in that this mutation was not identified in 40 normal controls (80 alleles) or in 52 CFC individuals (104 alleles) we have sequenced to date ( [18]; Rauen, unpublished data). Interestingly, although we had not identified this MEK1 p.D67N mutant in our CFC cohort, this same MEK1 mutation has recently been reported as a germline mutation in CFC syndrome [29]. In addition to a MEK1 mutation, ES-2 also had a B-Raf p.V600E missense substitution. These two mutations may have been co-operating tumorigenic events. What makes this finding particularly interesting is the fact that previous sequencing studies of the MEK1/2 protein kinase domain failed to identify any mutations in gliomas, testicular germ cell tumors, breast cancer and lung cancer [35]-[38]. Notably, the p.D67N in ES-2 falls outside the protein kinase domain which spans from AA 68-271 (). Many germline CFC mutations are located 5' of the protein kinase domain ([18], [29], [39]; Rauen, unpublished data). Functional studies of these novel CFC mutants have demonstrated increased activity in vitro over wildtype MEK in stimulating ERK phosphorylation, but these CFC mutants are not as active as an artificially generated constitutively active MEK mutant ([18]; Rauen, unpublished data). Other studies have demonstrated that alteration of the N-terminus of MEK increases the basal kinase activity implicating an important regulatory role along with substrate recognition [40]-[42].
###end p 41
###begin p 42
###xml 583 587 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-RodriguezViciana1">[18]</xref>
To assess the functional consequence of MEK1 p.D67N, this amino acid substitution was analyzed by SIFT and found to be functionally affected. To corroborate this information, MEK1 p.D67N was transiently transfected into HEK 293T cells, and ERK phosphorylation was measured by Western blot analysis. The MEK1 p.D67N mutant is activating as demonstrated by increased ERK phosphorylation as compared to empty vector and wildtype MEK1, two controls which do not activate ERK. However, the level of ERK phosphorylation for p.D67N is less than the positive control CFC MEK1 p.Y130C mutant [18].
###end p 42
###begin p 43
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 387 391 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Bansal1">[43]</xref>
###xml 428 432 428 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
In addition to BRAF and MEK1 mutations, several synonymous database SNP were also identified. B-Raf p.G634G (rs9648696) was identified in 40% of the 15 cell lines, MEK2 p.I220I (rs10250) was present in 73% and MEK2 p.D151D (rs17851657) was identified in 33% of the cell lines. These synonymous database SNPs were present at a frequency which is comparable to that previously reported (; [43]). There was one uniquely identified MEK1 SNP in OVCAR 10 resulting from a nt 348 heterozygous G-->A transition in exon 3, p.Q113Q. All synonymous SNPs were characterized by SIFT and determined to be tolerated.
###end p 43
###begin p 44
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Hoshino1">[15]</xref>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 486 490 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 624 628 624 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 633 637 633 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK2</italic>
###xml 902 906 902 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-SeboltLeopold1">[16]</xref>
###xml 1027 1031 1027 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001279-Solit1">[44]</xref>
###xml 362 369 <span type="species:ncbi:9606">patient</span>
Our findings emphasize that mutations which alter function of the MAPK pathway play an important role in ovarian cancer [15]. In addition, the identification of mutations in key MAPK pathway components will be important in determining the responsiveness of the cancer to therapeutics, the aggressive and metastatic behavior of the tumor and the prognosis of the patient. Four of 15 (26%) cell lines in this study had BRAF mutations and 1 of 15 (7%) had a MEK mutation. It is known that BRAF mutations have been identified in certain types of ovarian cancer; however, mutations in the downstream effectors of B-Raf including MEK1 and MEK2 may also be important contributors of ovarian cancer tumorigenesis. Defining the pathogenetics of ovarian cancer may enable the use of targeted therapeutics, such as small molecule inhibitors of MAPK pathway, which have recently begun to demonstrate great promise [16]. In addition, a report indicates that cells with activated B-Raf have enhanced, selective sensitivity to MEK inhibitors [44]. Our results underscore the importance that further characterization of the sensitivity of various BRAF and MEK mutants to small molecule inhibition is an important avenue to pursue towards the development of effective treatments for ovarian cancer.
###end p 44
###begin title 45
Methods
###end title 45
###begin title 46
Cell Lines and Isolation of Genomic DNA
###end title 46
###begin p 47
###xml 53 61 53 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 492 497 <span type="species:ncbi:9606">human</span>
Fifteen ovarian cancer cell lines, commonly used for in vitro experiments, were screened for mutations: OVCAR 3, SKOV 3, TOV-112d, A2780, OV90, ES-2, TOV-21g, Caov-3, A1847, IGROV 1, OVCAR 5, 2008, OVCAR 10, PEO1 and Hey. Cell pellets from each of these cell lines were kindly provided by Drs. Charles Drescher and Beatrice Knudsen. Genomic DNA was isolated from cell pellets using the QIAamp DNA Tissue kit (Qiagen, Valencia, CA), according to the manufacturer's instructions. Forty healthy human controls were included in this study. Genomic DNA was isolated from peripheral blood lymphocytes using the QIAamp DNA Blood Midi kit (Qiagen, Valencia, CA), according to the manufacturer's instructions. Control samples were obtained under an approved institution review board from the University of California San Francisco.
###end p 47
###begin title 48
PCR and Bidirectional Sequencing
###end title 48
###begin p 49
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK2</italic>
###xml 150 157 150 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001279-t004">Table 4</xref>
###xml 162 169 162 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001279-t005">Table 5</xref>
###xml 256 273 256 273 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GTAAAACGACGGCCAGT</named-content>
###xml 288 306 288 306 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CAGGAAACAGCTATGACC</named-content>
PCR primers were designed to amplify all coding exons and intronic flanking regions of BRAF (NM_004333.2), MEK1 (NM_002755.2) and MEK2 (NM_030662.2) (Table 4 and Table 5). For sequencing, the PCR primers were modified on the 5' end to include M13 forward (GTAAAACGACGGCCAGT) and reverse (CAGGAAACAGCTATGACC) sequences. PCR and sequencing were performed by Agencourt Bioscience Corporation (Beverly, MA). Bidirectional sequencing was conducted with ABI BigDye v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) according to manufacturer's guidelines and run on an ABI3730xl capillary sequencing instrument (Applied Biosystems, Foster City, CA).
###end p 49
###begin title 50
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
BRAF Sequencing Primers.
###end title 50
###begin title 51
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK2</italic>
MEK1 and MEK2 Sequencing Primers.
###end title 51
###begin title 52
Analysis
###end title 52
###begin p 53
Sequencing data was analyzed using two sequence analysis programs, PolyPhred Software v5.02 (University of Washington, Seattle, WA) and SeqScape(R) Software (Applied Biosystems, Foster City, CA). In addition, manual review was conducted with Mutation Surveyor 3.00 (SoftGenetics LLC, State College, PA). Further evaluation of detected nucleotide mutations consisted of Sorting Intolerant From Tolerant (SIFT; blocks.fhcrc.org/sift/SIFT.html) and screening against known databases: NCBI, Cosmic, UniProtKB/Swiss-Prot and JSNP (, , ca.expasy.org/sprot/, snp.ims.u-tokyo.ac.jp/).
###end p 53
###begin title 54
Plasmids
###end title 54
###begin p 55
###xml 6 10 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 111 115 111 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human MEK1 cDNA (Origene, Rockville, MD) was cloned into a pcDNA3 vector with a Myc-tag at the N-terminus. The MEK1 nt 199 G-->A transition was introduced using Quick-Change Site-Directed Mutagenesis (Stratagene, La Jolla, CA) and verified by direct sequencing.
###end p 55
###begin title 56
Transient Transfections and Western Blot Analysis
###end title 56
###begin p 57
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 297 303 <span type="species:ncbi:9913">bovine</span>
Human embryonic kidney (HEK) 293T cells were seeded the day before in six-well dishes and transfected, in duplicate, with 2 microg total plasmid DNA and 5 microl of Lipofectamine 2000 (Life Technologies, Carlsbad, CA) according to manufacturer's instructions. Cells were serum-starved (0.5% fetal bovine serum) and 24 hours later lysed in buffer containing Protease and Phosphatase Inhibitor cocktails (Sigma, St. Louis, MO). Expression levels of myc-MEK, total ERK and phosphorylated ERK were analyzed by Western blot. Myc (A-14) and p-ERK(E-4) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and p44/42 MAP Kinase antibody was purchased from Cell Signaling Technology (Danvers, MA).
###end p 57
###begin p 58
###xml 22 28 <span type="species:ncbi:9135">Canary</span>
The authors thank the Canary Foundation () for financial and scientific support and Drs. Ingrid Revet and William Tidyman for thoughtful comments and technical assistance.
###end p 58
###begin title 59
References
###end title 59
###begin article-title 60
Cancer statistics, 2007.
###end article-title 60
###begin article-title 61
###xml 30 35 <span type="species:ncbi:9606">human</span>
Mutations of the BRAF gene in human cancer.
###end article-title 61
###begin article-title 62
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.
###end article-title 62
###begin article-title 63
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
###end article-title 63
###begin article-title 64
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
###end article-title 64
###begin article-title 65
PIK3CA mutations in ovarian cancer.
###end article-title 65
###begin article-title 66
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
###end article-title 66
###begin article-title 67
PIK3CA mutations in advanced ovarian carcinomas.
###end article-title 67
###begin article-title 68
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
###end article-title 68
###begin article-title 69
Allelic imbalance and mutations of the PTEN gene in ovarian cancer.
###end article-title 69
###begin article-title 70
Single mutations of the PTEN gene in recurrent ovarian carcinomas.
###end article-title 70
###begin article-title 71
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
###end article-title 71
###begin article-title 72
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
###end article-title 72
###begin article-title 73
The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions.
###end article-title 73
###begin article-title 74
###xml 96 101 <span type="species:ncbi:9606">human</span>
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors.
###end article-title 74
###begin article-title 75
Targeting the mitogen-activated protein kinase cascade to treat cancer.
###end article-title 75
###begin article-title 76
Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.
###end article-title 76
###begin article-title 77
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.
###end article-title 77
###begin article-title 78
A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.
###end article-title 78
###begin article-title 79
Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors.
###end article-title 79
###begin article-title 80
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
###end article-title 80
###begin article-title 81
Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations.
###end article-title 81
###begin article-title 82
###xml 47 52 <span type="species:ncbi:9606">human</span>
High-throughput oncogene mutation profiling in human cancer.
###end article-title 82
###begin article-title 83
The RAF proteins take centre stage.
###end article-title 83
###begin article-title 84
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
###end article-title 84
###begin article-title 85
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.
###end article-title 85
###begin article-title 86
Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
###end article-title 86
###begin article-title 87
###xml 31 36 <span type="species:ncbi:9606">human</span>
Comparative properties of five human ovarian adenocarcinoma cell lines.
###end article-title 87
###begin article-title 88
CFC and Noonan syndromes due to mutations in RAS/MAPK signaling pathway: genotype/phenotype relationships and overlap with Costello syndrome.
###end article-title 88
###begin article-title 89
Characterization of four novel epithelial ovarian cancer cell lines.
###end article-title 89
###begin article-title 90
Absence of BRAF and NRAS mutations in uveal melanoma.
###end article-title 90
###begin article-title 91
A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma.
###end article-title 91
###begin article-title 92
SIFT: Predicting amino acid changes that affect protein function.
###end article-title 92
###begin article-title 93
Predicting the effects of amino Acid substitutions on protein function.
###end article-title 93
###begin article-title 94
###xml 55 60 <span type="species:ncbi:9606">human</span>
Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults.
###end article-title 94
###begin article-title 95
###xml 55 60 <span type="species:ncbi:9606">human</span>
Somatic mutations of the protein kinase gene family in human lung cancer.
###end article-title 95
###begin article-title 96
###xml 66 71 <span type="species:ncbi:9606">human</span>
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
###end article-title 96
###begin article-title 97
###xml 104 109 <span type="species:ncbi:9606">human</span>
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer.
###end article-title 97
###begin article-title 98
Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: Overlapping clinical manifestations with Costello syndrome.
###end article-title 98
###begin article-title 99
Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.
###end article-title 99
###begin article-title 100
A novel regulatory mechanism in the mitogen-activated protein (MAP) kinase cascade. Role of nuclear export signal of MAP kinase kinase.
###end article-title 100
###begin article-title 101
Mitogen-activated protein (MAP) kinase phosphorylation of MAP kinase kinase: determination of phosphorylation sites by mass spectrometry and site-directed mutagenesis.
###end article-title 101
###begin article-title 102
###xml 70 75 <span type="species:ncbi:9606">human</span>
Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines.
###end article-title 102
###begin article-title 103
BRAF mutation predicts sensitivity to MEK inhibition.
###end article-title 103
###begin p 104
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 104
###begin p 105
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 63 69 <span type="species:ncbi:9135">Canary</span>
###xml 111 117 <span type="species:ncbi:9135">Canary</span>
Funding: NIH grant HD048502 (K.A.R.) provided partial funding. Canary Foundation provided partial funding. The Canary Foundation did not have a role in the collection, analysis, and interpretation of data.
###end p 105

